⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 30 in last 7 days 🍎 Food: 2 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 42 seconds ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 30 in last 7 days 🍎 Food: 2 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 42 seconds ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT August 24, 2026

Cinglan 60 mg-Filmtabletten 60 mg (Filmtablette)

📷 Wikipedia: Cinacalcet · Source
Cinglan 60 mg-Filmtabletten 60 mg (Filmtablette)
📷 Wikipedia: Cinacalcet · Source
Parallel export is prohibited.
⚠️
Shortage ongoing
CINACALCET HYDROCHLORID is currently in short supply in AT.
📈 Timeline
18 days active so far
August 25, 2026 September 11, 2026

What is this? Cinglan 60 mg is a medicine with the active ingredient cinacalcet. It comes as small tablets in a blister pack.

What's happening? The 30-tablet pack is out of stock. It is expected back in pharmacies on 23 October.

Does this affect me? If you take Cinglan 60 mg, you may not find it now. Check with your pharmacist.

What should I do? Ask your pharmacist or doctor for advice before changing how you take your medicine.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
CINACALCET HYDROCHLORID
Agency-published detail

🚫 Parallel export ban active · ATC: H05BX01 · Reason: Regulatorische Änderungen · Marketing authorisation holder: G.L. Pharma GmbH, Schloßplatz 1, 8502 Lannach, Österreich · Affected packs: 30 Stück Schachtel, Blisterpackung [Nicht verfügbar, since 2026-08-24, resupply 2026-10-23]

First published
August 24, 2026
Last refreshed by us
18 hours ago
Severity (as classified)
High
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

Related alerts

High AT resolved 5 months ago

Cinacalcet ratiopharm 90 mg Filmtabletten 90 mg (Filmtablette)

Cinacalcet ratiopharm 90 mg film-coated tablets are not available for parallel export.
High AT resolved 6 months ago

Cinacalcet ratiopharm 30 mg Filmtabletten 30 mg (Filmtablette)

Parallel export is banned for Cinacalcet ratiopharm 30 mg film-coated tablets. Supply is delayed.
High AT resolved 10 months ago

Cinacalcet ratiopharm 60 mg Filmtabletten 60 mg (Filmtablette)

Cinacalcet ratiopharm 60 mg film-coated tablets are unavailable due to a manufacturing delay.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Cinglan 60 mg-Filmtabletten 60 mg (Filmtablette). Parallel export is prohibited.
▸ When was this alert issued?
This alert was issued on August 24, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Serious risk. A serious risk means the product or medicine can cause significant harm. Treat the alert as urgent.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.